Cargando…

Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome

Background: Recently, anti-PD-1 antibodies plus lenvatinib has been administered in a series of solid tumors. Yet, the efficacy of chemo-free treatment of this combined therapy has seldom been reported in gallbladder cancer (GBC). The aim of our study was to initially evaluate the efficacy of the ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Tiantian, Pu, Changsheng, Wu, Xianjia, Wang, Qiang, Zhang, Keming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252738/
https://www.ncbi.nlm.nih.gov/pubmed/37296684
http://dx.doi.org/10.3390/diagnostics13111833
_version_ 1785056242464456704
author Wu, Tiantian
Pu, Changsheng
Wu, Xianjia
Wang, Qiang
Zhang, Keming
author_facet Wu, Tiantian
Pu, Changsheng
Wu, Xianjia
Wang, Qiang
Zhang, Keming
author_sort Wu, Tiantian
collection PubMed
description Background: Recently, anti-PD-1 antibodies plus lenvatinib has been administered in a series of solid tumors. Yet, the efficacy of chemo-free treatment of this combined therapy has seldom been reported in gallbladder cancer (GBC). The aim of our study was to initially evaluate the efficacy of the chemo-free treatment in unresectable GBCs. Methods: We retrospectively collected the clinical data of unresectable GBCs treated using chemo-free anti-PD-1 antibodies plus lenvatinib in our hospital from March 2019 to August 2022. The clinical responses were assessed, and PD-1 expression was evaluated. Results: Our study enrolled 52 patients, with the median progression-free survival being 7.0 months and the median overall survival being 12.0 months. The objective response rate was 46.2% and the disease control rate was 65.4%. The expression of PD-L1 in patients with objective response was significantly higher than those with progression of disease. Conclusions: For patients with unresectable GBC, when not eligible for systemic chemotherapy, chemo-free treatment using anti-PD-1 antibodies with lenvatinib may become a safe and rational choice. The expression of PD-L1 in tumor tissues may be correlated to the objective response, and thus is expected to be a predictor of efficacy, and further clinical studies are certainly needed.
format Online
Article
Text
id pubmed-10252738
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102527382023-06-10 Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome Wu, Tiantian Pu, Changsheng Wu, Xianjia Wang, Qiang Zhang, Keming Diagnostics (Basel) Article Background: Recently, anti-PD-1 antibodies plus lenvatinib has been administered in a series of solid tumors. Yet, the efficacy of chemo-free treatment of this combined therapy has seldom been reported in gallbladder cancer (GBC). The aim of our study was to initially evaluate the efficacy of the chemo-free treatment in unresectable GBCs. Methods: We retrospectively collected the clinical data of unresectable GBCs treated using chemo-free anti-PD-1 antibodies plus lenvatinib in our hospital from March 2019 to August 2022. The clinical responses were assessed, and PD-1 expression was evaluated. Results: Our study enrolled 52 patients, with the median progression-free survival being 7.0 months and the median overall survival being 12.0 months. The objective response rate was 46.2% and the disease control rate was 65.4%. The expression of PD-L1 in patients with objective response was significantly higher than those with progression of disease. Conclusions: For patients with unresectable GBC, when not eligible for systemic chemotherapy, chemo-free treatment using anti-PD-1 antibodies with lenvatinib may become a safe and rational choice. The expression of PD-L1 in tumor tissues may be correlated to the objective response, and thus is expected to be a predictor of efficacy, and further clinical studies are certainly needed. MDPI 2023-05-23 /pmc/articles/PMC10252738/ /pubmed/37296684 http://dx.doi.org/10.3390/diagnostics13111833 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wu, Tiantian
Pu, Changsheng
Wu, Xianjia
Wang, Qiang
Zhang, Keming
Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome
title Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome
title_full Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome
title_fullStr Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome
title_full_unstemmed Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome
title_short Chemo-Free Treatment Using Anti-PD-1 Antibodies with Lenvatinib in Unresectable Gallbladder Cancer: PD-L1 May Be a Potential Biomarker for a Better Outcome
title_sort chemo-free treatment using anti-pd-1 antibodies with lenvatinib in unresectable gallbladder cancer: pd-l1 may be a potential biomarker for a better outcome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252738/
https://www.ncbi.nlm.nih.gov/pubmed/37296684
http://dx.doi.org/10.3390/diagnostics13111833
work_keys_str_mv AT wutiantian chemofreetreatmentusingantipd1antibodieswithlenvatinibinunresectablegallbladdercancerpdl1maybeapotentialbiomarkerforabetteroutcome
AT puchangsheng chemofreetreatmentusingantipd1antibodieswithlenvatinibinunresectablegallbladdercancerpdl1maybeapotentialbiomarkerforabetteroutcome
AT wuxianjia chemofreetreatmentusingantipd1antibodieswithlenvatinibinunresectablegallbladdercancerpdl1maybeapotentialbiomarkerforabetteroutcome
AT wangqiang chemofreetreatmentusingantipd1antibodieswithlenvatinibinunresectablegallbladdercancerpdl1maybeapotentialbiomarkerforabetteroutcome
AT zhangkeming chemofreetreatmentusingantipd1antibodieswithlenvatinibinunresectablegallbladdercancerpdl1maybeapotentialbiomarkerforabetteroutcome